Does the blood pressure-lowering effect of statins contribute to their beneficial cardiovascular effects?

References

• Strandberg TE, Salommaa VV, Naukkarinen VA et al. Long-term mortality after 5-year multifactorial primary prevention of cardiovascular disease in middle-aged men. JAMA266, 1225–1229 (1991).
   PubMed Web of Science ®Google Scholar
• Lipid Research Clinics Program. The lipid research clinic’s coronary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA251, 351–364 (1984).
   PubMed Web of Science ®Google Scholar
• Clofibrate and niacin in coronary heart disease. JAMA231, 360–381 (1975).
   PubMed Web of Science ®Google Scholar
• Ravnskov U. Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. Br. Med. J.305, 15–19 (1992).
   PubMed Web of Science ®Google Scholar
• Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentration and mortality: a quantitative rewiew of primary prevention trials. Br. Med. J.301, 309–314 (1990).
   PubMed Web of Science ®Google Scholar
• Brugts JJ, Yetgin T, Hoeks SE et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. Br. Med. J.338, 2376–2384 (2009).
   PubMed Web of Science ®Google Scholar
• Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation109, 39–43 (2004).
   Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FAH et al. For the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med.359, 2195–2207 (2008).
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M et al.; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med.357, 2109–2122 (2007).
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Akdim F, Stroes ES et al.; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med.358, 1431–1443 (2008).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek EJ et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med.361, 2113–2122 (2009).
   PubMed Web of Science ®Google Scholar
• The ACCORD Study Group. Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med.362(17), 1563–1574 (2010).
   PubMed Web of Science ®Google Scholar
• Bays HE, Maccubbin D, Meehan AG, Kuznetsova O, Mitchel YB, Paolini JF. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients. Clin. Ther.31, 115–122 (2009).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med.333, 1301–1307 (1995).
   PubMed Web of Science ®Google Scholar
• The Scandinavian Simvastatin Survival Study Group (4S). Randomized trial of cholesterol lowering in 4444 patients with coronary heart desease. Lancet344, 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA288, 2998–3007 (2002).
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR et al.; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet361, 1149–1158 (2003).
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet360, 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Glorioso N, Troffa C, Filigheddu F et al. Effect of the HMG–CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension34, 1281–1286 (1999).
   PubMed Web of Science ®Google Scholar
• Ikeda T, Sakurai J, Nakayama D et al. Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs. Am. J. Hypertens.17, 502–506 (2004).
   PubMed Web of Science ®Google Scholar
• Terzoli L, Mircoli L, Raco R, Ferrari U. Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors. J. Cardiovasc. Pharmacol.46, 310–315 (2005).
   PubMed Web of Science ®Google Scholar
• Lopau K, Spindler K, Wanner C. Effects of pravastatin treatment on blood pressure regulation after renal transplantation. Kidney Blood Press. Res.29, 329–337 (2006).
   PubMed Web of Science ®Google Scholar
• Borghi C, Dormi A, Veronesi M, Sangiorgi Z, Gaddi A. Brisighella Heart Study Working Party Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am. Heart J.148, 285–292 (2004).
   PubMed Web of Science ®Google Scholar
• Strazzullo O, Kerry SM, Barbato A, Versiero M, D’elia L, Cappuccio FP. Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials. Hypertension49, 792–798 (2007).
   PubMed Web of Science ®Google Scholar
• Golomb BA, Dimsdale JE, White HL, Richie JB, Criqui MH. Reduction in blood pressure with statins. Results from the UCSD statin study, a randomized trial. Arch. Intern. Med.168, 721–727 (2008).
   PubMed Web of Science ®Google Scholar
• Prandin MG, Cicero AF, Dormi A, Veronesi M, Cosentino ER, Borghi C. Prospective evaluation of the effect of statins on blood pressure control in hypertensive patients in clinical practice. Nutr. Metab. Cardiovasc. Dis. DOI: 10.1016/j.numecd.2009.05.010 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Williams B, Lacy PS, Cruickshank K et al.; CAFE and ASCOT Investigators. Impact of statin therapy on central aortic pressures and hemodynamics. Principal results of the Conduit Artery Function Evaluation-Lipid–Lowering Arm (CAFE–LLA) Study. Circulation119, 53–61 (2009).
   PubMed Web of Science ®Google Scholar
• Mancia G, Parati G, Revera M et al. Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial. Br. Med. J.340, c1197 (2010).
   PubMedGoogle Scholar
• Savoia C, Schiffrin EL. Reduction of C-reactive protein and the use of anti-hypertensives. Vasc. Health Risk Manag.3, 975–983 (2007).
   PubMedGoogle Scholar